Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or immediate plans for fundraising through debt or equity in the Q3 FY24 earnings call. The management emphasized focusing on cost-cutting, operational improvements, and achieving positive EBITDA next year. Cash utilization plans are contingent upon completing the simplification of the corporate structure, which is currently delaying liquidity deployment. Cash is largely held in a subsidiary, making direct utilization tax-inefficient until simplification is done. No direct reference to new debt or equity fundraising was made; management is prioritizi

Any current/future capex/capital investment/strategic investment?

No significant warehouse expansion plans in the next 1-2 quarters; current seven warehouses sufficient for planned growth (Page 14). Capex requirements are minimal, with a focus on cost efficiency and stability (Page 15). No plans to start offline presence despite having no agreement restricting it; focus remains on RetailerShakti digital model (Page 15). Investment and growth focus predominantly on RetailerShakti platform and technology enhancement (Page 4, 5). Exploring product credit offerings to retailers in collaboration with FinTechs, NBFCs, and banks, which may be a future strategic inv

Future growth expectations in sales/revenue/volumes?

RetailerShakti is identified as the clear growth engine for SastaSundar, expected to deliver substantial growth going forward. The company is targeting around 15,000 actively transacting retailers by the end of the fiscal year, up from about 11,100 currently. Retailer additions are ongoing, including expansion into newer geographies like the northeast, with approximately 1,000 retailers being added quarterly. Growth derives both from acquiring new retailers and increasing wallet share of existing retailers. Healthbuddy growth has slowed and is expected to remain flat or modest; management focu

Future growth expectations in earnings/operating earnings/profits/EPS?

EBITDA expected to turn positive next year due to cost-cutting and growth in RetailerShakti. Operational cash positive status anticipated in the next fiscal year. Company targeting INR500 crores revenue run rate soon, up from current INR360 crores. RetailerShakti identified as the primary growth engine over Healthbuddy/Flipkart tie-up. Gross margin improvement expected over 2 years, with potential 3%-4% increase via higher procurement margin. Short-term gross margin around 10% not achievable, but sustainable growth prioritized over fast expansion. Cost reductions underway, especially in operat

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders. The company has highlighted growth in its Retailer Shakti business with over 11,100 unique retailers placing orders in the recent quarter, up from approximately 9,680 in the previous quarter. Average invoice value for Retailer Shakti was around INR 1.33 lakhs in the recent quarter, up from INR 1.27 lakhs earlier. The company is expanding into new geographies, including northeast India, indicating expectation of increasing orders. There is no specific quantitative data shared on order backlog or pen

Health X Platform LtdQ3 FY24Healthcare Services

Health X Platform Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹273Market Cap: ₹918 CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

0 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

RetailerShakti is identified as the clear growth engine for SastaSundar, expected to deliver substantial growth going forward.
The company is targeting around 15,000 actively transacting retailers by the end of the fiscal year, up from about 11,100 currently.
Retailer additions are ongoing, including expansion into newer geographies like the northeast, with approximately 1,000 retailers being added quarterly.
Growth derives both from acquiring new retailers and increasing wallet share of existing retailers.
Healthbuddy growth has slowed and is expected to remain flat or modest; management focus has shifted towards RetailerShakti.
Industry discounting has normalized, leading to sustainable but slower e-pharmacy growth (20%-30% year-on-year).
Revenue for RetailerShakti grew ~20% quarter-on-quarter recently, with operational profitability expected soon.
No formal revenue guidance is provided, but management is confident in the growth prospects of the RetailerShakti platform.

Margin guidance

Category 2

EBITDA expected to turn positive next year due to cost-cutting and growth in RetailerShakti.
Operational cash positive status anticipated in the next fiscal year.
Company targeting INR500 crores revenue run rate soon, up from current INR360 crores.
RetailerShakti identified as the primary growth engine over Healthbuddy/Flipkart tie-up.
Gross margin improvement expected over 2 years, with potential 3%-4% increase via higher procurement margin.
Short-term gross margin around 10% not achievable, but sustainable growth prioritized over fast expansion.
Cost reductions underway, especially in operational expenses related to RetailerShakti.
Simplification of corporate structure pending, expected to aid better liquidity utilization and shareholder returns.
No formal revenue or profitability guidance provided due to market uncertainties.

See what Health X Platform Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or immediate plans for fundraising through debt or equity in the Q3 FY24 earnings call.
The management emphasized focusing on cost-cutting, operational improvements, and achieving positive EBITDA next year.
Cash utilization plans are contingent upon completing the simplification of the corporate structure, which is currently delaying liquidity deployment.
Cash is largely held in a subsidiary, making direct utilization tax-inefficient until simplification is done.
No direct reference to new debt or equity fundraising was made; management is prioritizing sustainability and organic growth via RetailerShakti.
The company expects to work on structural simplification before any cash deployment or external financing decisions are made.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders.
The company has highlighted growth in its Retailer Shakti business with over 11,100 unique retailers placing orders in the recent quarter, up from approximately 9,680 in the previous quarter.
Average invoice value for Retailer Shakti was around INR 1.33 lakhs in the recent quarter, up from INR 1.27 lakhs earlier.
The company is expanding into new geographies, including northeast India, indicating expectation of increasing orders.
There is no specific quantitative data shared on order backlog or pending orders.
Management focuses on strengthening Retailer Shakti and addressing challenges in Healthbuddy supply chain, indicating ongoing order fulfillment.
No forward-looking guidance on orders or revenue is provided due to industry uncertainties.

See what Health X Platform Ltd management said on order book — free account, 30 seconds.

Capex plans

No significant warehouse expansion plans in the next 1-2 quarters; current seven warehouses sufficient for planned growth (Page 14).
Capex requirements are minimal, with a focus on cost efficiency and stability (Page 15).
No plans to start offline presence despite having no agreement restricting it; focus remains on RetailerShakti digital model (Page 15).
Investment and growth focus predominantly on RetailerShakti platform and technology enhancement (Page 4, 5).
Exploring product credit offerings to retailers in collaboration with FinTechs, NBFCs, and banks, which may be a future strategic investment area (Page 14).
No detailed guidance given on revenue or profitability projections or specific capital expenditure for future quarters (Page 14).

Track Health X Platform Ltd — get its next earnings analysis in your feed

How does Health X Platform Ltd rank vs peers in Healthcare Services?

Pro feature

ThisHealth X Platform Ltd

Rev 3Mar 2

See where Health X Platform Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Health X Platform Ltd rank in Healthcare Services?

Compare Health X Platform Ltd against every Healthcare Services company (Q3 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Health X Platform Ltd's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →